必须声明标量变量 "@Script_ID"。 环孢素联用伏立康唑致免疫性血小板减少症患者血药浓度显著升高分析-《赣南医学院学报》

[1]倪 斌,方春云,李 燕,等.环孢素联用伏立康唑致免疫性血小板减少症患者血药浓度显著升高分析[J].赣南医学院学报,2019,39(12):1244-1246.[doi:10.3969/j.issn.1001-5779.2019.12.015]
 NI Bin,FANG Chun-yun,LI Yan,et al.Analysis of high CsA blood concentration Induced by the Combination of Cyclosporine A and Voriconazole in patient with immune thrombocytopenia[J].,2019,39(12):1244-1246.[doi:10.3969/j.issn.1001-5779.2019.12.015]
点击复制

环孢素联用伏立康唑致免疫性血小板减少症患者血药浓度显著升高分析()
分享到:

《赣南医学院学报》[ISSN:1001-5779/CN:36-1154/R]

卷:
39
期数:
2019年12期
页码:
1244-1246
栏目:
个案报道
出版日期:
2019-12-31

文章信息/Info

Title:
Analysis of high CsA blood concentration Induced by the Combination of Cyclosporine A and Voriconazole in patient with immune thrombocytopenia
文章编号:
1001-5779(2019)12-1244-03
作者:
倪 斌1方春云2李 燕1唐远鹏1严金玲1
赣南医学院第一附属医院 1.药学部; 2.妇产科,江西 赣州 341000
Author(s):
NI Bin1 FANG Chun-yun2 LI Yan1 TANG Yang-peng1 YANG Jin-ling1
The First Affiliated Hospital, Gannan Medical University 1.Department of pharmacy; 2.Gynaecology and Obstetrics, Ganzhou, Jiangxi 341000
关键词:
环孢素 伏立康唑 免疫性血小板减少症 药物相互作用
Keywords:
Cyclosporin A Voriconazole immune thrombocytopenia Drug-drug interaction
分类号:
R558
DOI:
10.3969/j.issn.1001-5779.2019.12.015
文献标志码:
A
摘要:
目的:分析免疫性血小板减少症患者环孢素A(cyclosporin A,CsA)血药浓度显著升高并导致患者肝功能异常原因,促进临床合理用药,减少药品不良反应发生。方法:通过对本案例分析,查阅相关文献,从吸收、代谢及排泄等方面分析CsA血药浓度显著升高并导致肝功能异常的原因,制定给药剂量调整方案并进行护肝治疗。结果:伏立康唑联用CsA致CsA血药浓度显著升高,经调整患者给药剂量CsA血药浓度达到平稳; 护肝治疗后,肝功能恢复正常。结论:临床上联合使用CsA和伏立康唑治疗时,应注意监测CsA血药浓度,及时调整CsA剂量,降低药品不良反应发生率。
Abstract:
Objective: Therapeutic drug monitoring(TDM)of cyclosporin A(CsA)was performed in a patient with immune thrombocytopenia, abnormal high blood concentration of CsA and hepatic dysfunction were noticed. Methods: The medication information of the patient during hospitalization as well as the related medical literature was collected. Then the cause of the abnormal high blood CsA and hepatic dysfunction were analyzed from four aspects including absorption factors, Metabolic factors, excretion factors. Results: The analysis suggested that the main reason of the abnormal high CsA blood concentration and hepatic dysfunction were due to the drug interaction between CsA and voriconazole used in combination. After dosage adjustment, the CsA blood concentration returned normal. Conclusions: The study indicated that when combinated use of CsA and voriconazole is performed, more attention should be paid to CsA blood concentration and the dose of CsA should be timely adjusted, so as to reduce the incidence of adverse drug reactions.

参考文献/References:

[1] 葛均波,徐永键.内科学[M].第8版.北京:人民卫生出版社,2013:625.
[2] 杜迪,李维亮,辛华雯.环孢素A的药物基因组学研究进展[J].中国药师,2018,21(4):695-700.
[3] 刘志艳, 陈恳, 刘园园, 等. 伏立康唑对免疫抑制剂药代动力学影响的系统评价[J].临床药物治疗杂志2016, 14(6): 21-26.
[4] Jeong S, Nguyen PD, Desta Z. Comprehensive in vitro analysis of voriconazole inhibition of eight cytochromeP450(CYP)enzymes: major effect on CYPs 2B6, 2C9, and 3A[J]. Antimicrob Agents Chemother, 2009, 53(2):541-551.
[5] 王广飞,卢金淼,李琴,等.环孢素A联用伏立康唑致噬血细胞综合征患儿血药浓度显著升高1例分析[J].药物流行病学杂志,2018, 27(9):617-620.
[6] Wilkinson GR. Drug metabolism and variability among patients in drug response[J]. New England Journal of Medicine, 2005,352(21): 2211-2221.
[7] Edwards DJ, Fitzsimmons ME, Schuetz EG, et al. 6',7'-Di hydroxybergamottin in grapefruit juice and Seville orange juice: effects on cyclosporine disposition, enterocyte CYP3A4, and P-glycoprotein[J]. Clinical Pharmacology & Therapeutics, 1999, 65(3): 237.
[8] Masoumi HT, Hadjibabaie M, Vaezi M, et al. Evaluation of the Interaction of Intravenous and Oral Voriconazole with Oral Cyclosporine in Iranian HSCT Patients[J]. Journal of Research in Pharmacy Practice, 2017, 6(2): 77-82.
[9] 董海燕,封卫毅,任晓东,等.伏立康唑治疗重症患者侵袭性真菌感染的回顾性分析[J].中国药房,2015(5): 606-609.
[10] Wang CE, Lu KP, Chang Z, et al. Association of CYP3A4* 1B genotype with Cyclosporin A pharmacokinetics in renal transplant recipients: A meta-analysis[J]. Gene, 2018,(664): 44-49.
[11] Coto E, Tavira B. Pharmacogenetics of calcineurin inhibitors in renal transplantation[J]. Transplantation, 2009, 88(88): 62-67.
[12] Hesselink DA, Van GT, van Schaik RH. The pharmacogenetics of calcineurin inhibitors: one step closer toward individualized immunosuppression?[J]. Pharmacogenomics, 2005, 6(4): 323-337.

备注/Memo

备注/Memo:
作者简介:倪斌,男,硕士,主管药师,主要从事医院药学工作。E-mail:823570378@qq.com
通信作者:严金玲,男,学士,主任药师,主要从事临床药学。E-mail:gzyanjinling@163.com
更新日期/Last Update: 2019-12-30